Cemiplimab (Libtayo) — CPB 0942 | AETNA Coverage Update

Aetna modified CPB 0942 for cemiplimab-rwlc (Libtayo), effective September 26, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated Clinical Policy Bulletin 0942 governing cemiplimab-rwlc (Libtayo) coverage for commercial medical plans. The CPB 0942 Aetna policy covers HCPCS code J9119 (cemiplimab-rwlc, 1 mg) and spans a wide range of oncology diagnoses — 779 ICD-10-CM codes in total. If your team bills for immunotherapy infusions across head and neck cancers or other solid tumors, this policy update directly affects your precertification workflow and site-of-care requirements.

Quick-Reference Table

Aetna Cemiplimab Coverage Policy and Medical Necessity Requirements 2025

The Aetna cemiplimab coverage policy under CPB 0942 applies to commercial medical plan members only. Medicare criteria are handled separately — if you have Medicare patients receiving Libtayo, check Aetna's Medicare Part B step therapy criteria, not this bulletin.

The central medical necessity requirement here is precertification. Every Aetna participating provider and member in an applicable plan design must get precertification before administering cemiplimab-rwlc. There are no exceptions built into this bulletin for urgency or continuity of care.

To request prior authorization, call (866) 752-7021 or fax (888) 267-3277. You can also submit a Statement of Medical Necessity via Aetna's Specialty Pharmacy Precertification forms. Build that step into your infusion scheduling workflow now — not after the drug is ordered.

The real issue with this policy is the site-of-care layer. Aetna's Site of Care Utilization Management Policy applies to cemiplimab-rwlc. That means Aetna will review where the infusion happens, not just whether it's medically necessary. If your practice administers Libtayo in a hospital outpatient setting when a lower-cost alternative site is available, expect scrutiny — and potential claim denial.

Aetna Cemiplimab Exclusions and Non-Covered Indications

The policy summary does not enumerate specific excluded indications within this bulletin. However, the coverage policy is selective by design. HCPCS codes J9022 (atezolizumab), J9023 (avelumab), J9271 (pembrolizumab), and J9299 (nivolumab) are listed in the bulletin as related codes — not covered codes under this CPB.

That distinction matters. These are checkpoint inhibitors in the same drug class as cemiplimab. Their presence in the bulletin signals that Aetna tracks cemiplimab billing against PD-1/PD-L1 alternatives. If your clinical team switches a patient between agents, verify that the new agent has its own active authorization. Don't assume a cemiplimab auth transfers to pembrolizumab or nivolumab.

Coverage Indications at a Glance

Aetna Cemiplimab Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Cemiplimab Under CPB 0942

HCPCS Codes — Covered When Selection Criteria Are Met

HCPCS Codes — Related (Not Covered Under CPB 0942)

CPT Codes — Chemotherapy Administration (Related to CPB 0942)

These CPT codes cover the administration services tied to cemiplimab-rwlc infusions. Bill the code that matches the actual administration method and time.

Key ICD-10-CM Diagnosis Codes

The full policy includes 779 ICD-10-CM codes. Below is a representative sample of the head and neck oncology diagnoses included. Confirm the complete list in the full CPB 0942 document before billing.

The full CPB 0942 policy includes 779 ICD-10-CM codes. Access the complete code list at app.payerpolicy.org/p/aetna/0942.

A note on cemiplimab billing reimbursement: J9119 is dosed per 1 mg. Cemiplimab is administered at 350 mg every three weeks or 350 mg every three weeks for four cycles then 700 mg every four weeks, depending on the indication. That means a single infusion generates a large unit count on J9119. A miscounted dose is a significant reimbursement error in either direction — underbilling or overbilling. Verify the ordered dose against the billed units on every claim.